Open AccessPrognostic Impact of Immunohistochemical and Molecular Features of Diffuse Large B-cell Lymphoma
Author(s) -
Е. В. Харченко,
А. С. Артемьева,
Ilia Poliatskin,
Т. Ю. Семиглазова
Publication year - 2019
Publication title -
medicinskij alfavit
Language(s) - English
Resource type - Journals
eISSN - 2949-2807
pISSN - 2078-5631
DOI - 10.33667/2078-5631-2019-2-17(392)-5-7
Subject(s) - lymphoma , rituximab , diffuse large b cell lymphoma , immunohistochemistry , epigenetics , pathogenesis , disease , medicine , pathology , cell of origin , cancer research , biology , cancer , gene , genetics
Diffuse large B-cell lymphoma is the most common type of non-Hodgkin’s lymphoma. Despite of dramatic improvement during last decades in rituximab-era, 30 % of patients are still resistant to initial therapy. Molecular genetics made significant contribution in our understanding of pathogenesis of disease, genetic and epigenetic disorders which have direct impact on cell’s growth, differentiation and immune response. This allowed distinguishing more aggressive subtypes of diffuse large B-cell lymphoma, which can potentially benefit from early-treatment intensification. In this review, we will discuss immunohistochemical and molecular features of diffuse large B-cell lymphoma and its impact on course, prognosis and response to therapy.